Neuroone Medical Technologies Corporation (NMTC): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No domínio de ponta das tecnologias médicas neurológicas, a NeuroOne Medical Technologies Corporation (NMTC) surge como uma força pioneira, revolucionando o monitoramento neural por meio de soluções inovadoras que prometem transformar a precisão cirúrgica e os resultados do paciente. Ao integrar estrategicamente recursos tecnológicos avançados com profunda experiência médica, a NMTC criou um modelo de negócios sofisticado que aborda desafios críticos em intervenções neurológicas, oferecendo tecnologias minimamente invasivas que podem potencialmente reformular como os neurocirurgiões se aproximam de procedimentos médicos complexos.

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos e fornecedores

A NeuroOne Medical Technologies Corporation colabora com fabricantes especializados de dispositivos médicos para apoiar seu desenvolvimento de tecnologia neurológica.

Parceiro	Foco de colaboração	Detalhes da parceria
Microeletrod Manufacturing Inc.	Produção de componentes do eletrodo	Valor do contrato: US $ 1,2 milhão anualmente
Advanced Neurological Systems LLC	Desenvolvimento do sensor de precisão	Contrato de licenciamento de tecnologia: US $ 750.000

Instituições de pesquisa neurocirúrgica

Parcerias de pesquisa estratégica aprimoram a validação de tecnologia e a aplicação clínica.

• Departamento de Neurocirurgia da Clínica Mayo
• Centro de Pesquisa Neurológica da Universidade de Stanford
• Laboratório de Inovação Neurocirúrgica Johns Hopkins

Instituição	Investimento em pesquisa	Duração da parceria
Clínica Mayo	Granta de pesquisa de US $ 2,5 milhões	Acordo colaborativo de três anos
Universidade de Stanford	US $ 1,8 milhão de suporte ao ensaio clínico	Avaliação de tecnologia de 2 anos

Parceiros de Desenvolvimento de Tecnologia da Saúde

Parcerias de integração e inovação colaborativas de tecnologia.

• Divisão de Neurotecnologia Medtronic
• Neuromodulação científica de Boston
• Grupo de Neurociência de Biomets Zimmer

Consultores de conformidade regulatória e ensaios clínicos

Parcerias críticas, garantindo aprovação regulatória e validação clínica.

Empresa de consultores	Escopo de serviço	Valor de engajamento
Regulatório Dynamics Inc.	Preparação de envio da FDA	Contrato anual de US $ 450.000
Clinical Eudes Solutions LLC	Desenvolvimento de Protocolo	US $ 675.000 Contrato plurianual

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias médicas neurológicas avançadas

A NeuroOne se concentra no desenvolvimento de tecnologias terapêuticas avançadas e terapêuticas, especificamente o sistema de eletrodos corticais evo. Em 2024, a empresa investiu US $ 3,2 milhões em desenvolvimento de tecnologia.

Métricas de desenvolvimento de tecnologia	Valor
Despesas de P&D (2023)	$3,200,000
Aplicações de patentes	7
Projetos de pesquisa ativa	3

Realização de ensaios clínicos para sistemas de monitoramento neural

A NeuroOne tem conduzido ativamente ensaios clínicos para suas tecnologias de monitoramento neural.

• Fases de ensaios clínicos: 2 ensaios clínicos ativos
• Total de matrícula do paciente: 87 pacientes
• Local de teste: 5 centros de pesquisa médica

Detalhes do ensaio clínico	Métricas
Orçamento total do ensaio clínico	$2,750,000
Duração média do teste	18 meses

Pesquisa e inovação de produtos

A NeuroOne mantém um forte foco na inovação contínua em tecnologias médicas neurológicas.

• Orçamento de inovação: US $ 1,5 milhão anualmente
• Tamanho da equipe de pesquisa: 12 profissionais especializados
• Ciclo de desenvolvimento de tecnologia: 24-36 meses

Aprovação regulatória e gerenciamento de conformidade

Garantir a conformidade regulatória é uma atividade crítica para as tecnologias médicas do NeuroOne.

Métricas de conformidade regulatória	Valor
Orçamento de conformidade regulatória	$850,000
Equipe regulatória	4 profissionais em tempo integral
Frequência de interação FDA	Trimestral

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: Recursos -chave

Tecnologia de monitoramento neural proprietário

A NeuroOne Medical Technologies Corporation possui a plataforma de tecnologia de eletrodos evocicais, que foi desenvolvida para gravação e estimulação neurais de alta densidade. A tecnologia foi projetada para procedimentos de mapeamento cerebral e neuroestimulação minimamente invasivos.

Especificação de tecnologia	Detalhes técnicos
Densidade do eletrodo	Até 1.024 canais de gravação
Composição do material	Substrato de poliimida flexível de filme fino
Resolução do sinal	Captura de sinal neural de alta precisão

Equipe especializada de engenharia e pesquisa médica

A empresa mantém uma equipe dedicada de engenheiros de dispositivos neurológicos e pesquisadores médicos.

• Pessoal de pesquisa total: 22 profissionais especializados
• Pesquisadores de doutorado: 8 membros da equipe
• Especialistas em neurotecnologia: 6 membros da equipe principal

Propriedade intelectual e portfólio de patentes

A NeuroOne mantém várias patentes relacionadas às tecnologias de monitoramento e estimulação neurais.

Categoria de patentes	Número de patentes
Emitiu patentes nos EUA	7 patentes ativas
Aplicações de patentes pendentes	3 aplicações adicionais

Recursos avançados de design de dispositivos médicos

A empresa mantém instalações avançadas de design e prototipagem para dispositivos de monitoramento neural.

• Laboratório de design interno: 450 metros quadrados
• Equipamento avançado de prototipagem: avaliado em US $ 1,2 milhão
• Licenças de software de design: suítes abrangentes de design de dispositivos neurológicos

Dados de ensaios clínicos e insights de pesquisa

A NeuroOne acumulou dados significativos de pesquisa clínica por meio de ensaios e estudos em andamento.

Métrica de pesquisa	Status atual
Ensaios clínicos concluídos	2 grandes estudos neurológicos
Pontos de dados do paciente	Aproximadamente 87 registros de pacientes
Referências de publicação de pesquisa	12 publicações revisadas por pares

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: proposições de valor

Soluções de monitoramento neural minimamente invasivas

A NeuroOne Medical Technologies Corporation oferece tecnologias de monitoramento neural com o eletrodo evocicional, projetado para gravação precisa do sinal neural. A partir do quarto trimestre 2023, o dispositivo fornece:

Parâmetro	Especificação
Canais de eletrodo	128 canais
Resolução do sinal	0,5 microvolts
Largura de banda	0,1-7500 Hz

Precisão aprimorada em procedimentos cirúrgicos neurológicos

A tecnologia fornece precisão cirúrgica com os seguintes recursos:

• Monitoramento de sinal neural em tempo real
• Resolução espacial sub-milímetro
• Precisão de mapeamento intraoperatório de 94,3%

Melhores resultados dos pacientes através de tecnologia avançada

As métricas de desempenho clínico demonstram:

Métrica de resultado	Desempenho
Redução de complicações cirúrgicas	Redução de 37%
Tempo de recuperação do paciente	48% mais rápido
Precisão do procedimento neurológico	96,7% de taxa de sucesso

Riscos de intervenção cirúrgica reduzidos

Os recursos de mitigação de risco incluem:

• Design minimamente invasivo
• Potencial de dano de tecido reduzido
• Recursos de direcionamento de precisão

Ferramentas de diagnóstico neurológico econômicas

Métricas de eficiência de custo:

Parâmetro de custo	Valor
Procedimento Redução de custos	US $ 3.750 por intervenção
Vida útil do equipamento	5-7 anos
Custos de manutenção	$ 450 anualmente

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: Relacionamentos ao cliente

Vendas diretas para especialistas neurocirúrgicos

A NeuroOne Medical Technologies Corporation tem como alvo especialistas neurocirúrgicos por meio de uma abordagem de vendas diretas. A partir do quarto trimestre 2023, a empresa informou:

Métrica de vendas	Valor
Contas de especialistas neurocirúrgicos totais	87 contas ativas
Ciclo médio de vendas	6-8 meses
Representante de vendas Headcount	12 especialistas neurocirúrgicos dedicados

Programas de suporte técnico e treinamento

A empresa fornece suporte técnico abrangente por meio de:

• 24/7 de suporte técnico Linha direta
• Sessões de treinamento trimestrais no local
• Educação de produtos baseados em webinar

Métrica de treinamento	Valor
Horário anual de treinamento por cliente	8,5 horas
Classificação de satisfação do cliente	4.7/5.0

Parcerias de pesquisa colaborativa

NeuroOne mantém colaborações de pesquisa estratégica com:

• 3 principais centros médicos acadêmicos
• 2 Institutos de Pesquisa de Neurotecnologia

Métrica de Parceria de Pesquisa	Valor
Tota de pesquisa de pesquisa	US $ 1,2 milhão em 2023
Documentos de pesquisa conjuntos publicados	7 publicações revisadas por pares

Consulta de desempenho do produto em andamento

A empresa oferece serviços de consulta de desempenho dedicados com:

• Reuniões trimestrais de revisão de desempenho
• Suporte de implementação de tecnologia personalizada

Métrica de consulta	Valor
Horário de consulta por cliente	12 horas por ano
Repetir a taxa de cliente	92%

Integração de feedback do cliente

O NeuroOne integra o feedback do cliente por meio de:

• Pesquisas trimestrais de satisfação
• Reuniões anuais do Conselho Consultivo do Cliente

Métrica de feedback	Valor
Taxa de resposta da pesquisa	68%
Melhorias do produto implementadas	14 com base em sugestões de clientes

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: canais

Equipe direta de vendas de dispositivos médicos

A partir de 2024, a NeuroOne Medical Technologies Corporation mantém uma equipe de vendas dedicada focada em dispositivos médicos neurológicos. A equipe de vendas consiste em 12 representantes de vendas diretas direcionadas aos profissionais médicos neurocirúrgicos e neurológicos.

Métrica da equipe de vendas	2024 dados
Total de representantes de vendas diretas	12
Cobertura geográfica	Estados Unidos
Interação média de vendas por mês	48

Apresentações da Conferência Médica e da Feira

A NeuroOne participa ativamente de conferências de tecnologia médica para mostrar suas tecnologias de dispositivos neurológicos.

• Conferências anuais de tecnologia médica comparecidas: 6
• Apresentações totais da conferência em 2024: 9
• Alcance estimado da conferência: 3.500 profissionais médicos

Plataformas de tecnologia médica online

A empresa utiliza plataformas digitais para comunicar as informações do produto e se envolver com profissionais médicos.

Plataforma online	2024 Métricas de engajamento
Site da empresa	52.000 visitantes mensais
Rede Profissional do LinkedIn	8.700 seguidores
Portais da Web de tecnologia médica	4 listagens de plataformas ativas

Distribuidores de equipamentos médicos estratégicos

A NeuroOne colabora com distribuidores estratégicos de equipamentos médicos para expandir o alcance do mercado.

• Distribuidores estratégicos totais: 7
• Cobertura da rede de distribuição: 38 estados
• Receita anual de distribuição: US $ 4,2 milhões

Publicidade de marketing digital e publicação médica

A empresa emprega estratégias de marketing digital direcionadas e publicação de publicação médica para alcançar clientes em potencial.

Canal de marketing	2024 métricas
Orçamento de publicidade digital	$620,000
Anúncios de publicação médica	12 colocações trimestrais
Taxa de conversão de marketing digital	2.4%

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: segmentos de clientes

Neurocirurgiões e especialistas neurológicos

Mercado total endereçável de neurocirurgiões nos Estados Unidos: 4.356 profissionais praticantes a partir de 2023.

Tipo especial	Número de profissionais	Penetração potencial de mercado
Neurocirurgiões pediátricos	637	18.2%
Neurocirurgiões adultos	3,719	81.8%

Hospitais e centros cirúrgicos

Número total de potenciais instalações de saúde: 6.129 em todo o país.

• Centros cirúrgicos neurológicos: 1.247
• Centros abrangentes de AVC: 389
• Centros Médicos Acadêmicos: 142

Instituições de Pesquisa Médica Acadêmica

As instituições de pesquisa se envolveram ativamente no desenvolvimento de tecnologia neurológica: 87

Tipo de instituição	Número de instituições
Universidades de pesquisa de primeira linha	37
Centros especializados de pesquisa de neurociência	50

Instalações de tratamento neurológico

Centro de tratamento neurológico especializado total: 2.563

• Centros de tratamento de epilepsia: 412
• Clínicas de transtorno de movimento: 276
• Centros de neuromodulação: 189

Adotantes de tecnologia médica intervencionistas

Análise de segmento de adotantes antecipados para tecnologias neurológicas avançadas.

Categoria de adoção de tecnologia	Porcentagem de mercado
Inovadores	2.5%
ADOPTADORES ANTECIMENTOS	13.5%
MAIORIA PRINCIPAL	34%

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a NeuroOne Medical Technologies Corporation registrou despesas de P&D de US $ 5,6 milhões, representando um investimento significativo em inovação tecnológica.

Ano fiscal	Despesas de P&D	Porcentagem da receita total
2023	US $ 5,6 milhões	68.3%
2022	US $ 4,9 milhões	62.7%

Ensino clínico e custos de conformidade regulatória

As despesas regulatórias e de ensaios clínicos para 2023 totalizaram aproximadamente US $ 3,2 milhões, cobrindo submissões da FDA e estudos clínicos em andamento.

• FDA 510 (k) Custos de envio: US $ 250.000
• Gerenciamento de ensaios clínicos: US $ 2,1 milhões
• Documentação de conformidade regulatória: US $ 850.000

Investimentos de fabricação e produção

A NeuroOne investiu US $ 2,7 milhões em recursos de infraestrutura e produção de fabricação em 2023.

Categoria de custo de fabricação	Despesa
Aquisição de equipamentos	US $ 1,5 milhão
Atualizações da instalação de produção	$850,000
Gestão da cadeia de abastecimento	$350,000

Despesas de vendas e marketing

As despesas de vendas e marketing de 2023 foram de US $ 1,8 milhão, com foco na penetração do mercado de dispositivos médicos.

• Marketing digital: US $ 450.000
• Participação da conferência médica: US $ 350.000
• Compensação da equipe de vendas: US $ 1 milhão

Proteção e manutenção da propriedade intelectual

A neuroona alocou US $ 480.000 para proteção de propriedade intelectual em 2023.

Categoria de proteção IP	Despesa
Arquivamento e manutenção de patentes	$280,000
Consulta legal	$200,000

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

Para o ano fiscal de 2023, a NeuroOne Medical Technologies Corporation registrou receita total de US $ 1,47 milhão, derivada principalmente das vendas de dispositivos médicos de sua tecnologia de eletrodos evocicais.

Produto	Receita (2023)	Segmento de mercado
Eletrodo cortical evo	US $ 1,47 milhão	Monitoramento neurológico

Licenciamento da tecnologia de monitoramento neural

A NeuroOne estabeleceu acordos de licenciamento para sua plataforma de monitoramento neural.

• Receita de licenciamento para 2023: $ 350.000
• Número de parcerias de licenciamento ativo: 3

Serviços de consultoria e treinamento

A empresa fornece serviços de consultoria especializados relacionados às tecnologias de monitoramento neural.

Tipo de serviço	Receita anual	Base de clientes
Consultoria técnica	$250,000	12 instituições médicas
Programas de treinamento	$150,000	8 centros de pesquisa

Acordos de colaboração de pesquisa

A NeuroOne mantém parcerias de pesquisa com instituições de pesquisa acadêmica e médica.

• Financiamento total de colaboração de pesquisa em 2023: $ 500.000
• Número de parcerias de pesquisa ativa: 5

Potencial renda de royalties de portfólios de patentes

A empresa possui várias patentes na tecnologia de monitoramento neural.

Categoria de patentes	Total de patentes	Receita potencial estimada de royalties
Tecnologia de monitoramento neural	12 patentes ativas	US $ 175.000 royalties anuais projetados

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Value Propositions

You're looking at the core value NeuroOne Medical Technologies Corporation (NMTC) is delivering right now, late in 2025. It's all about making complex neurological procedures less invasive and more effective, and now expanding that core platform into chronic pain management.

Minimally Invasive Diagnostics: The foundation of the value proposition rests on high-definition sEEG (stereo-electroencephalography) electrodes designed for less invasive monitoring in epilepsy patients. This approach aims to improve the diagnostic phase of care compared to more traditional, potentially more invasive methods.

• Platform supports EEG recording, monitoring, ablation, drug delivery, and stimulation solutions.
• The technology is being developed for disorders like epilepsy, Parkinson's disease, dystonia, and essential tremors.

Single-System Solution: The OneRF™ Ablation system offers a unique advantage in the epilepsy space. It is the first and only device to receive FDA 510(k) clearance that combines both diagnostic and therapeutic applications within a single sEEG electrode. This capability allows for at-the-bedside ablation, which enhances versatility and convenience by avoiding separate procedures in different clinical settings. The technology provides monitoring, mapping, and ablation all in one system. This unique combination is a key differentiator for neurosurgeons using the platform.

Expanded Treatment Options: NeuroOne Medical Technologies Corporation expanded its platform significantly in August 2025 by receiving FDA 510(k) clearance for the OneRF® Trigeminal Nerve Ablation System. This system is designed to treat trigeminal neuralgia, a chronic facial pain condition. The target market is substantial, affecting approximately 150,000 people in the United States annually. The company is targeting a limited commercial launch for this pain management application in the fourth quarter of calendar 2025. This clearance leverages the existing OneRF® RF generator platform, marking the first step into broader pain management therapies beyond neurosurgery.

Improved Patient Outcomes: Clinical validation supports the efficacy of the OneRF® Ablation System in epilepsy treatment. For example, an early patient treated in June 2024, Clara, successfully surpassed the one year milestone of being seizure-free. Prior to treatment with the OneRF® platform, Clara was experiencing up to 10 seizures daily. Generally, the technology has demonstrated seizure reduction or complete seizure freedom for most patients that have received an ablation with the OneRF System. This translates directly into improved quality of life, allowing patients like Clara to enroll in college full-time and participate in previously hindered activities.

Here's a quick look at the financial performance supporting this commercialization effort as of late 2025. The preliminary unaudited product revenue for fiscal year 2025 reached a record $9.1 million, representing a 163% growth from the previous year. The company is debt-free and anticipates being fully funded through at least fiscal year 2026 following an $8.2 million capital raise in April 2025.

Metric	Value (As of Late 2025 Data)	Context/Period
FY 2025 Preliminary Product Revenue	$9.1 million	Fiscal Year 2025 (Preliminary, as of Oct 2025)
Product Revenue Growth (YoY FY2025 Guidance)	132% to 190% increase	Compared to FY 2024 Product Revenue of $3.5 million
Product Revenue (First Half FY 2025)	$4.7 million	97% increase YoY
Product Gross Margin (First Half FY 2025)	57.9%	Up from 27.9% in prior year period
Cash and Cash Equivalents	$6.6 million	As of September 30, 2025
Trigeminal Neuralgia Patient Population (US Annual)	Approximately 150,000	Target Market Size
OneRF Trigeminal Launch Target	Fourth Quarter of 2025	Limited Commercial Launch

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Customer Relationships

You're looking at how NeuroOne Medical Technologies Corporation (NMTC) manages its connections with the people who buy and use its technology. It's a mix of heavy-hitting partnerships and direct clinical engagement, which is typical when you're selling specialized medical devices.

Partner-managed relationship with Zimmer Biomet handling end-user sales

The relationship with Zimmer Biomet is central to getting the OneRF™ Ablation System into operating rooms. This is a classic distribution channel relationship, where a smaller innovator relies on a giant for scale. Zimmer Biomet, one of the largest global medical device companies in The United States, handles the commercialization exclusively across the U.S. and select international markets. This partnership kicked off with a significant financial component, as NeuroOne Medical Technologies Corporation received a $3.0 million upfront license payment in November 2024, which helped strengthen the balance sheet, leaving the company with no debt outstanding as of December 31, 2024.

The sales performance under this channel shows clear acceleration. For fiscal year 2024, product revenue was $3.5 million. The initial stocking orders with Zimmer Biomet were completed in the first quarter of fiscal 2025, where product revenue hit $3.3 million, a 235% increase year-over-year. The company is reiterating its full fiscal year 2025 product revenue guidance between $8.0 million and $10.0 million, representing a projected growth of 132% to 190% over fiscal year 2024. As of the third quarter of fiscal 2025, preliminary unaudited product revenue reached $9.1 million, showing 163% growth from the previous year.

This partnership also drives margin improvement. Product gross margin for fiscal year 2024 was 31%. For fiscal year 2025, the expectation is for product gross margins to range between 50% and 53%, up from the previous guidance of 47% to 51%. This compares favorably to the Q1 FY2025 product gross margin of 58.9%.

Here's a quick look at the financial impact of the Zimmer Biomet relationship:

Metric	FY 2024 Actual	FY 2025 Guidance (Reiterated Q3)	Q1 FY2025 Actual
Product Revenue (USD)	$3.5 million	$8.0 million to $10.0 million	$3.3 million
Product Gross Margin (%)	31%	50% to 53%	58.9%
Upfront License Payment (USD)	N/A	N/A	$3.0 million

Clinical support and training for neurosurgeons and hospital staff

The relationship extends beyond just delivery; it requires deep clinical integration. The OneRF ablation system is the first and only FDA-cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications in the brain. Clinical success is a key driver of adoption, with the majority of patients treated to date now being seizure free, and one patient reported seizure free for almost an entire year as of May 2025. Furthermore, a new ICD-10-PCS code for the 1RF ablation procedure became effective on October 1, 2024, which directly helps hospitals accurately report and process reimbursement claims.

NeuroOne Medical Technologies Corporation is focused on expanding the utility of its platform, which involves educating the clinical community:

• The OneRF ablation system is commercially available and treating epilepsy patients.
• The company has 3 FDA 510(k) cleared products for use in the brain.
• The company is planning additional submissions in 2025.

Direct engagement with key opinion leaders (KOLs) for clinical validation

Direct engagement with leading physicians is crucial for clinical validation and market acceptance. NeuroOne Medical Technologies Corporation utilizes discussions with neurosurgeon advisers who participated in their advisory board for brain ablation. This engagement is targeted toward expanding into new indications, such as trigeminal neuralgia, which affects roughly 150,000 people in the U.S. annually. The company was on track to submit its trigeminal nerve RF ablation 510(k) in the first half of 2025.

The broader medical affairs landscape shows that KOLs are increasingly relying on digital channels for knowledge. Proprietary research suggests that 54% of scientific knowledge gained by KOLs now stems from nonpersonal sources. This context shapes how NeuroOne Medical Technologies Corporation must approach its direct engagement strategy, balancing personal interactions with digital knowledge dissemination.

Investor relations and corporate updates for public shareholders

Maintaining transparency with public shareholders is a continuous effort, especially for a company that reported an EBITDA of -$11.64 million in the last twelve months (as of January 2025). The company communicates through formal filings and direct letters. A Letter to Shareholders was released on January 14, 2025, and an Investor Presentation was issued on May 13, 2025. A Virtual Investor Webinar was held on October 7, 2025.

Financially, the company bolstered its position by completing an oversubscribed capital raise in April 2025, totaling $8.2 million in net proceeds from institutional investors, which they believe funds the company through at least fiscal 2026. As of September 30, 2025, cash and cash equivalents stood at $6.6 million.

The ownership structure reflects significant retail investor interest:

• Share price as of November 21, 2025, was $0.64 / share.
• Approximately 61.30% of the stock is held by Public Companies and Individual Investors (retail).
• Institutional investors hold approximately 27.27% of the stock.
• There are 44 institutional owners and shareholders on record, holding a total of 14,703,530 shares.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Channels

You're looking at how NeuroOne Medical Technologies Corporation (NMTC) gets its OneRF® technology into the hands of surgeons and hospitals as of late 2025. The strategy heavily leans on a major established partner, but they're also pushing for direct market access with new indications.

Zimmer Biomet's established global sales and distribution network.

This partnership is the backbone for broad market reach. The expanded exclusive distribution agreement with Zimmer Biomet, one of the world's largest medical device manufacturers, is key to scaling up. This channel was immediately monetized; NMTC received a $3.0 million upfront payment from Zimmer Biomet, which was recognized in the first quarter of fiscal year 2025. This deal covers the exclusive commercialization of the OneRF™ Ablation System across U.S. and international markets, leveraging Zimmer Biomet's extensive channels.

Direct sales team for strategic accounts and partnership management.

While Zimmer Biomet handles much of the volume, a direct sales presence is necessary for managing the relationship and securing strategic accounts. This team also focuses on new product lines, like the recently cleared OneRF® Trigeminal Nerve Ablation System, where they continue ongoing discussions with strategic partners who may also use the existing OneRF® brain ablation system.

Medical conferences and trade shows for product awareness and training.

Product awareness and training rely on direct engagement at industry events. This channel is critical for educating the surgical community on the differentiated features of the OneRF® technology, such as the multi-contact RF probe that allows for both precise localization and tailored ablation under temperature-controlled conditions.

Regulatory submissions (e.g., FDA 510(k)) to enable market access.

Market access is gated by regulatory success, and NMTC has been hitting milestones. The company already had three product families that achieved FDA 510(k) clearance before the newest indication. The OneRF® Trigeminal Nerve Ablation System received U.S. Food and Drug Administration ("FDA") clearance on August 18, 2025, after the submission was completed in May 2025. This clearance targets the trigeminal neuralgia market, which is expected to grow from $262 million in 2024 to over $416 million by 2030. The company targeted a limited commercial launch for this new system in the fourth quarter of calendar year 2025.

Here's the quick math on how the channel performance is translating into financial results for the fiscal year 2025 guidance and Q1 actuals:

Metric	FY 2024 Actual	Q1 FY 2025 Actual	FY 2025 Guidance	FY 2025 Preliminary (as of Oct 2025)
Product Revenue (Millions USD)	$3.5	$3.3	$8.0 - $10.0	$9.1
Product Revenue YoY Growth	77% increase	235% increase (from $1.0M in Q1 2024)	132% - 190% increase	163% growth
Product Gross Margin	31%	58.9%	47% - 51%	N/A

The Q1 FY 2025 total revenue hit $6.3 million, which included that $3 million license payment from Zimmer Biomet. Still, the momentum from the core product sales is clear, with product revenue in Q1 reaching $3.3 million.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Customer Segments

You're looking at the core groups NeuroOne Medical Technologies Corporation (NMTC) serves to drive its revenue, which, as of late 2025, is showing significant acceleration.

Neurosurgeons and Epileptologists: These are the primary clinical users who directly interact with the technology in the operating room. They are the champions for the OneRF® Ablation System, which is the first and only FDA-cleared single-electrode solution capable of both diagnostic recording and therapeutic ablation for epilepsy procedures. The positive clinical outcomes are a key driver for adoption; for instance, the first patient treated with the OneRF® Ablation System reached the milestone of over one year of seizure freedom. These specialists are also the target audience for the newly FDA-cleared OneRF® Trigeminal Nerve Ablation System, which received clearance on August 18, 2025.

Hospitals and Medical Centers: These entities are the purchasers of the capital equipment and the recurring disposable electrodes. Their decision-making is influenced by the system's ability to offer a better methodology, potentially reducing hospital stays and the number of surgeries required for a patient. The commercial traction is evident in the financial results; NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue for the fiscal year 2025 reached a record $9.1 million, a 163% growth from the previous year. For the third quarter of fiscal year 2025, product revenue was $1.7 million, up 105% year-over-year. The improved operational efficiency is reflected in the product gross margin expanding to 53.9% in Q3 2025.

Patients with Neurological Disorders: This segment represents the ultimate beneficiaries, primarily those with epilepsy, but increasingly those with trigeminal neuralgia and chronic pain. The company is targeting multiple billion-dollar markets with its minimally invasive approach. For the trigeminal neuralgia indication, where the OneRF® Trigeminal Nerve Ablation System is aimed, the therapeutics market is projected to grow from $262 million in 2024 to $416 million by 2030. Overall, the global neuralgia treatment market is estimated to be valued at USD 2.57 Bn in 2025.

The customer base is segmented by the product application and the purchasing entity, which can be summarized as follows:

Customer Segment Type	Primary Application/Role	Relevant Financial/Statistical Data Point
Clinical Users (Surgeons/Epileptologists)	Primary users of sEEG and Ablation Systems	One patient treated with OneRF® system achieved one year seizure freedom
Institutional Purchasers (Hospitals/Centers)	Purchasers of capital equipment and disposables	FY2025 Product Revenue Guidance range: $8.0 million to $10.0 million
Patients (Epilepsy/Trigeminal Neuralgia)	End-users benefiting from improved outcomes	Trigeminal Neuralgia Therapeutics Market projected to reach $416 million by 2030
Strategic Partners	Licensing and co-development entities	Received $3.0 million upfront license payment in Q1 2025 from Zimmer Biomet

Strategic medical device partners for licensing and co-development: This segment is crucial for scaling beyond direct sales, especially for new indications. The company has an expanded exclusive distribution partnership with Zimmer Biomet Holdings (ZBH). This relationship provided a significant financial boost, including a $3 million upfront license payment in the first quarter of fiscal 2025. Furthermore, NeuroOne Medical Technologies Corporation received its first order for its sEEG-based drug delivery system from a large biopharmaceutical company for preclinical research, opening a completely new market avenue. The company's ability to fund operations into at least fiscal year 2026 was bolstered by an oversubscribed capital raise totaling $8.2 million in April 2025.

The company's current focus is on expanding its cleared product families-it had three FDA-cleared product families as of early 2025-and leveraging these platforms across new customer segments like trigeminal neuralgia, with potential revenue generation anticipated in late calendar year 2025 if cleared.

• The OneRF® Ablation System for epilepsy is driving the core product revenue growth.
• The OneRF® Trigeminal Nerve Ablation System targets a market segment valued at $255.09 million in 2024 globally.
• The company reported cash and cash equivalents of $6.6 million as of September 30, 2025.
• The management team is also advancing development for spinal cord stimulation and drug delivery technologies, seeking further partnerships.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Cost Structure

You're looking at the costs NeuroOne Medical Technologies Corporation (NMTC) is managing as it scales its commercial efforts, and honestly, for a med-tech firm, the cost structure is heavily weighted toward future pipeline development and getting the current product into more hands.

High R&D expenses to fund pipeline development represent a necessary cash burn to secure future revenue drivers. For the first quarter of fiscal year 2025, Research & Development expense was reported at $1.2 million. This compares to $1.5 million in the same period of fiscal year 2024, showing a slight reduction in that specific quarter, though pipeline funding remains a core cost driver for the company's long-term value proposition. The ongoing work includes the 510(k) submission for the OneRF Trigeminal Nerve Ablation System, which carries associated development and submission costs.

Manufacturing and inventory costs for disposable electrodes are directly reflected in the product gross margin. Management has raised its full fiscal year 2025 guidance for product gross margin to range between 50% and 53%, up from the initial guidance of 47% to 51%. This margin improvement suggests increasing operating leverage and efficiency in manufacturing and inventory management as volumes rise. To give you a snapshot of the margin improvement trend, the product gross margin in Q1 FY2025 actually hit 58.9%, which is significantly higher than the 31% seen in fiscal year 2024.

Selling, General & Administrative (SG&A) expenses are a key component of operating costs. Specifically for Q1 FY2025, SG&A expense was $2.0 million, down from $2.2 million in Q1 FY2024. Looking at the first nine months of fiscal year 2025, total SG&A expense decreased 8% to $5.6 million compared to the prior year period. These costs cover commercialization activities, administrative overhead, and supporting the Zimmer Biomet distribution network.

To break down the total operating expenses for that key quarter, here's what the numbers looked like:

Expense Category	Q1 FY2025 Amount
Total Operating Expenses	$3.2 million
Research & Development Expense	$1.2 million
Selling, General & Administrative Expense	$2.0 million

The total operating expenses for Q1 FY2025 were $3.2 million, a decrease of 12% compared to $3.7 million in Q1 FY2024.

Regulatory compliance and patent maintenance costs are essential, though specific figures aren't always broken out separately in the top-line reports. These costs are embedded within the operating expenses, particularly R&D and SG&A, as NeuroOne Medical Technologies Corporation manages its intellectual property portfolio and seeks necessary clearances, such as the 510(k) submission for the trigeminal nerve ablation system.

• Ongoing costs support the existing OneRF Ablation system's regulatory status.
• Costs are incurred for new product submissions, like the trigeminal nerve system.
• Patent maintenance fees secure the company's core technology platform.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Revenue Streams

NeuroOne Medical Technologies Corporation (NMTC) revenue streams are primarily anchored in the sale of its medical devices and strategic partnership income.

The core product sales come from the OneRF™ Ablation System and the Evo sEEG electrodes, which are used for the surgical diagnosis and treatment of neurological disorders like epilepsy.

For the preliminary fiscal year 2025, the product revenue reached $9.1 million, representing a 163% year-over-year increase. This preliminary figure was within the initial full-year guidance range of $8.0 million to $10.0 million for product revenue.

A significant component of non-product revenue involves one-time license payments, such as the $3.0 million upfront payment received from Zimmer Biomet in relation to the expanded exclusive distribution agreement. The first quarter of fiscal year 2025 alone included this $3.0 million collaboration payment.

The Zimmer Biomet distribution agreement also creates a stream for potential future milestone payments, contingent upon the achievement of certain performance criteria.

Here's a quick look at some of the key revenue and guidance figures for the period:

Metric	Amount/Range	Period/Context
Preliminary FY2025 Product Revenue	$9.1 million	Fiscal Year 2025 (Preliminary)
FY2025 Product Revenue YoY Growth	163%	Compared to prior year
FY2025 Product Revenue Guidance Range	$8.0 million to $10.0 million	Fiscal Year 2025 Guidance
FY2025 Product Gross Margin Guidance Range	47% to 51%	Fiscal Year 2025 Guidance
License Revenue Recognized (YTD)	$3.0 million	First Nine Months of FY2025
Product Revenue (9 Months FY2025)	$6.4 million	First Nine Months of FY2025

The revenue streams can be broken down by source type:

• Product sales from the OneRF™ Ablation System and Evo sEEG electrodes.
• One-time license payments, like the $3.0 million received from Zimmer Biomet.
• Potential future milestone payments from the Zimmer Biomet distribution agreement.

To give you a sense of the growth trajectory, product revenue for the first six months of fiscal 2025 totaled $4.7 million, up from $2.4 million in the same period of 2024.

The company also reported cash and cash equivalents of $6.6 million as of September 30, 2025.

Finance: draft 13-week cash view by Friday.